Shandong Weigao Group Medical Polymer Company Limited (SHWGF)

Shandong Weigao Group Medical Polymer Company Limited (SHWGF) Healthcare & Pipeline Overview

Shandong Weigao Group Medical Polymer Company Limited, based in China, develops, produces, and sells single-use medical devices, including infusion devices, orthopedic products, and interventional instruments. Operating with a 15% profit margin and a 5% dividend yield, the company competes within the medical instruments and supplies sector, serving hospitals and medical units.

What Is the Investment Thesis for SHWGF?

Shandong Weigao Group Medical Polymer Company Limited presents a compelling investment case based on its established position in the Chinese medical device market and its diverse product portfolio. With a P/E ratio of 7.8 and a dividend yield of 5.00%, the company offers potential value and income. Growth catalysts include expanding its interventional and orthopedic product lines, as well as increasing its presence in the pharma packaging sector. The company's strong gross margin of 49.4% indicates efficient operations. However, investors may want to evaluate risks associated with operating in a regulated industry and the potential impact of competition. The company's beta of 0.19 suggests relatively low volatility compared to the broader market. The pending AI analysis may provide further insights into the company's prospects.

Based on FMP financials and quantitative analysis

SHWGF Key Highlights

• Market capitalization of $2.22B, reflecting its significant presence in the medical device market.
• P/E ratio of 7.8, suggesting a potentially undervalued investment relative to earnings.
• Profit margin of 15.0%, indicating efficient operations and profitability.
• Gross margin of 49.4%, demonstrating strong pricing power and cost management.
• Dividend yield of 5.00%, offering a substantial income stream for investors.

Who Are SHWGF's Competitors?

SHWGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SHWGF's Key Strengths?

• Diverse product portfolio covering multiple medical specialties.
• Established brand recognition in China.
• Strong manufacturing capabilities and cost-competitive production.
• Extensive distribution network across China.

What Are SHWGF's Weaknesses?

• Reliance on the Chinese market.
• Limited international presence compared to global competitors.
• Potential impact of regulatory changes in China.
• Dependence on single-use medical devices, which may face environmental concerns.

What Could Drive SHWGF Stock Higher?

• Expansion of production capacity to meet increasing demand for medical devices in China.
• Development and launch of new interventional and orthopedic products.
• Potential partnerships with international distributors to expand global reach.
• Government support for the medical device industry in China.
• AI analysis pending for SHWGF, which may reveal new insights.

What Are the Key Risks for SHWGF?

• Intense competition from domestic and international medical device manufacturers.
• Regulatory changes in China that could impact the company's operations.
• Product liability claims related to medical devices.
• Dependence on the Chinese market, which is subject to economic and political risks.
• Fluctuations in currency exchange rates that could impact export sales.

What Are the Growth Opportunities for SHWGF?

• Expansion of Orthopedic Product Line: Weigao has an opportunity to expand its orthopedic product line, targeting the growing demand for joint replacements and trauma fixation devices in China. The Chinese orthopedic market is estimated to reach $5 billion by 2028, driven by an aging population and increasing prevalence of osteoarthritis. Weigao's 'Wego Ortho' brand can leverage its existing distribution network and brand recognition to capture a larger market share.
• Growth in Interventional Products: The interventional product segment offers significant growth potential, particularly in the areas of cardiovascular and tumor interventions. The Chinese interventional device market is projected to grow at a CAGR of 10% over the next five years. Weigao can capitalize on this trend by developing and marketing innovative interventional instruments and implantation materials, leveraging its research and development capabilities.
• Increased Focus on Pharma Packaging: Weigao can further penetrate the pharma packaging market by offering high-quality prefilled syringes and other packaging solutions. The demand for advanced pharma packaging is increasing due to the growing biologics market and the need for improved drug delivery systems. The global pharma packaging market is expected to reach $125 billion by 2027. Weigao can leverage its existing polymer expertise and manufacturing capabilities to gain market share.
• Penetration of Blood Management Products: The blood management product segment presents growth opportunities through the development and sale of advanced blood collection, storage, and separation equipment. The increasing demand for safe and efficient blood transfusion practices is driving growth in this market. Weigao can expand its 'Hai Xing' brand by offering innovative blood management solutions to hospitals and blood stations across China.
• Expansion into International Markets: Weigao has the potential to expand its sales and distribution network beyond China. Southeast Asia, the Middle East, and Africa offer attractive growth opportunities due to their increasing healthcare expenditure and demand for affordable medical devices. Weigao can leverage its cost-competitive manufacturing base and established product portfolio to penetrate these markets, either through direct sales or strategic partnerships.

What Opportunities Does SHWGF Have?

• Expansion into international markets, particularly Southeast Asia and the Middle East.
• Growth in the interventional product segment.
• Increased focus on pharma packaging.
• Development of innovative medical devices through research and development.

What Threats Does SHWGF Face?

• Intense competition from both domestic and international players.
• Pricing pressures from healthcare reforms in China.
• Potential product liability claims.
• Impact of currency fluctuations on export sales.

What Are SHWGF's Competitive Advantages?

• Established brand recognition in the Chinese medical device market.
• Extensive product portfolio covering various medical specialties.
• Strong manufacturing capabilities and cost-competitive production.
• Extensive distribution network across China.
• Research and development capabilities for developing innovative medical devices.

What Does SHWGF Do?

Shandong Weigao Group Medical Polymer Company Limited, established in 2000 and headquartered in Weihai, China, specializes in the research, development, production, and sale of single-use medical devices. The company operates through six segments: Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others. Its product portfolio includes vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, specialized clinical collection kits, wound sutures, wound healing dressings, blood collection, storage, separation, and sterilization equipment. It also offers prefilled syringes, blood glucose testing devices, anesthesia consumables, ICU equipment, and surgical equipment. Weigao's orthopedic devices, tumor and blood vessel interventional instruments, implantation materials, and hemodialysis equipment are key components of its offerings. The company also produces medical PVC granules, plastic packing bags, carton boxes, and industrial automatic equipment. Its products are marketed under brands such as Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing. Weigao serves hospitals, blood stations, and other medical units, as well as distributors, primarily within the People's Republic of China. The company is also involved in finance leasing, factoring, wholesale of medical devices, and provides asset management and logistics services.

What Products and Services Does SHWGF Offer?

• Develops and manufactures single-use medical devices.
• Produces vascular and non-vascular access infusion devices.
• Offers orthopedic products, including joint replacements and trauma fixation devices.
• Provides interventional products for cardiovascular and tumor interventions.
• Manufactures pharma packaging products, such as prefilled syringes.
• Offers blood management products for collection, storage, and separation of blood.
• Produces anesthesia consumables, ICU equipment, and surgical equipment.

How Does SHWGF Make Money?

• Manufactures and sells single-use medical devices to hospitals, blood stations, and other medical units.
• Generates revenue through the sale of its products under various brands, including Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing.
• Distributes its products through a network of distributors and direct sales channels.
• Provides finance leasing and factoring services related to its products.

What Industry Does SHWGF Operate In?

Shandong Weigao Group Medical Polymer Company Limited operates in the growing medical device industry in China. The industry is driven by increasing healthcare expenditure, an aging population, and rising demand for advanced medical technologies. The Chinese medical device market is characterized by both domestic and international players, with competition intensifying across various product segments. Weigao's focus on single-use medical devices positions it to benefit from the increasing emphasis on infection control and patient safety. The company competes with both local and global companies, including ANSLF (Ansell Limited), ANSLY (Ansell Limited), BVNKF (B. Braun Melsungen AG), BVNRY (B. Braun Melsungen AG), and MAHLY (Mahle GmbH).

Who Are SHWGF's Key Customers?

• Hospitals and medical units across China.
• Blood stations and blood banks.
• Distributors of medical devices.
• Pharmaceutical companies (for pharma packaging products).

FY2026 estForward Outlook

Wall Street analysts project Shandong Weigao Group Medical Polymer Company Limited revenue of about $14.57B for fiscal 2026, with EPS near $0.39. The estimate reflects 7 contributing analysts.

SHWGF Valuation & Market Position

With a $2.22B market cap, Shandong Weigao Group Medical Polymer Company Limited sits in the mid-cap segment of the market. Relative to its peer group, SHWGF's quantitative score of 47/100 is roughly in line with the peer average of 53/100.

ROE 7%Key Financial Metrics

Return on equity for Shandong Weigao Group Medical Polymer Company Limited stands at 6.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.5%, showing how much profit it generates from its asset base. SHWGF trades at a trailing price-to-earnings ratio of 7.82, below the Healthcare sector average of ~23x. Its free cash flow yield is 7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 12.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Shandong Weigao Group Medical Polymer Company Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.30 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Shandong Weigao Group Medical Polymer Company Limited operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Weihai, CN. The company is led by CEO Rinan Cong. SHWGF has traded publicly since 2010.

SHWGF Financials

SHWGF Latest News

No recent news available for SHWGF.

SHWGF Analyst Consensus

SHWGF MoonshotScore

What Investors Ask About Shandong Weigao Group Medical Polymer Company Limited (SHWGF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources